Markets:

Overview

News

Currencies

International

Treasuries

Incannex Healthcare Inc. - Common Stock (NQ:IXHL)

0.4566 -0.0222 (-4.64%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

Incannex thrilled with positive pre-IND meeting for arthritis treatment

July 27, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting...

Via TheNewswire.com

Incannex thrilled with positive pre-IND meeting for arthritis treatment

July 27, 2023

--News Direct--

Via News Direct

Incannex Completes Positive Pre-IND Meeting With FDA On CBD-Based Drug For Treatment Of Rheumatoid Arthritis ↗

July 26, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has completed a constructive pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S.

Via Benzinga

Incannex Healthcare: Is Life Better On Nasdaq? ↗

July 24, 2023

Incannex Healthcare is planning to redomicile to the US in a move designed to access deeper pools of capital and increase the company’s long-term market valuation. We interview the CEO of the...

Via Talk Markets

Cannabis Stock Gainers And Losers From July 26, 2023 ↗

July 26, 2023

Via Benzinga

Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗

July 23, 2023

The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...

Via Talk Markets

Incannex Submits IND Application To The FDA For Dronabinol-Based Drug For Obstructive Sleep Apnea ↗

July 21, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has successfully submitted an Investigational New Drug (‘IND’) application to the US Food and Drug Administration for IHL-42X for treatment of...

Via Benzinga

Cannabis Stock Movers For July 19, 2023 ↗

July 19, 2023

Via Benzinga

Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial

July 18, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has engaged Fortrea as the contract research organisation (CRO) to manage the IND opening Phase 2/3 clinical...

Via TheNewswire.com

Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial

July 18, 2023

--News Direct--

Via News Direct

Fortrea To Manage Incannex's FDA IND Opening Phase 2/3 Trial Of Its Dronabinol-Based Drug For Obstructive Sleep Apnea ↗

July 18, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) has engaged Fortrea (NASDAQ: FTRE) as the contract research organisation for management of the IND opening p

Via Benzinga

Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗

July 14, 2023

Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.

Via Talk Markets

Incannex Receives HREC Approval For Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis ↗

July 13, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its...

Via Benzinga

Incannex CEO talks plans to redomicile to US

July 11, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun the process of shifting all outstanding shares to the Nasdaq after making the decision to redomicile...

Via TheNewswire.com

Incannex CEO talks plans to redomicile to US

July 11, 2023

Incannex CEO talks plans to redomicile to US

Via News Direct

Incannex To Redomicile To United States, List All Shares On Nasdaq ↗

July 10, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) intends to redomicile from Australia to the United States via proposed schemes of arrangement between Incannex and its shareholders (share scheme)...

Via Benzinga

Psychedelic Stocks Jumped 10% Last Week ↗

July 09, 2023

The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly

Via Talk Markets

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 06, 2023

Via Benzinga

Incannex Approved For Bioavailability Clinical Trial For Dronabinol-Based Drug For Treatment Of Obstructive Sleep Apnea ↗

July 06, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 06, 2023

Via Benzinga

Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗

July 01, 2023

Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up...

Via Talk Markets

Incannex appoints principal investigators for pivotal IHL-42X trial

June 19, 2023

Incannex appoints principal investigators for pivotal IHL-42X trial

Via News Direct

Incannex appoints principal investigators for pivotal IHL-42X trial

June 19, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X,...

Via TheNewswire.com

Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗

June 17, 2023

There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD.

Via Talk Markets

Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗

June 10, 2023

Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index

Via Talk Markets

Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More ↗

June 06, 2023

Major Investor Commits $30 Million To Psychedelics Funding

Via Benzinga

Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes ↗

June 05, 2023

NCIA Sacks Half Of Its Team To Increase Financial Strength

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.